The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
| Autor: | Lockhart SR; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Fothergill AW; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Iqbal N; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bolden CB; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Grossman NT; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Garvey EP; Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA., Brand SR; Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA., Hoekstra WJ; Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA., Schotzinger RJ; Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA., Ottinger E; National Institutes of Health, Therapeutics for Rare and Neglected Diseases, Bethesda, Maryland, USA., Patterson TF; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA South Texas Veterans Health Care System, San Antonio, Texas, USA., Wiederhold NP; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA wiederholdn@uthscsa.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2016 Mar 25; Vol. 60 (4), pp. 2528-31. Date of Electronic Publication: 2016 Mar 25 (Print Publication: 2016). |
| DOI: | 10.1128/AAC.02770-15 |
| Abstrakt: | Thein vitroactivities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel ofCryptococcus neoformansandCryptococcus gattiiisolates. VT-1129 demonstrated potent activities against bothCryptococcusspecies as demonstrated by low MIC50and MIC90values. ForC. gattii, thein vitropotency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole againstC. neoformans, including isolates with reduced fluconazole susceptibility. (Copyright © 2016, American Society for Microbiology. All Rights Reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|